Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.47 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25010327 | 1.00 | CRBN (0.60) | CRBNCSNK1A1IKZF2SALL4GSPT1 | |
| SCHEMBL30270700 | 0.90 | CRBN (0.58) | CRBNCSNK1A1IKZF2SALL4GSPT1 | |
| SCHEMBL25010621 | 0.90 | CRBN (0.58) | CRBNCSNK1A1IKZF2SALL4GSPT1 | |
| SCHEMBL25010179 | 0.87 | CRBN (0.69) | CRBNCSNK1A1IKZF2IKZF3DDB1 | |
| SCHEMBL25012172 | 0.86 | CRBN (0.63) | CRBNCSNK1A1IKZF2GSPT1IKZF3 | |
| SCHEMBL22713304 | 0.86 | CRBN (0.60) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL30270696 | 0.86 | CRBN (0.63) | CRBNCSNK1A1IKZF2GSPT1IKZF3 | |
| SCHEMBL25011304 | 0.86 | CRBN (0.63) | CRBNCSNK1A1IKZF2GSPT1IKZF3 | |
| SCHEMBL25010128 | 0.86 | CRBN (0.63) | CRBNCSNK1A1IKZF2GSPT1IKZF3 | |
| SCHEMBL30270637 | 0.86 | CRBN (0.63) | CRBNCSNK1A1IKZF2GSPT1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | CRBN, CLNS1A, CDR2 | CRBN 1/4885CSNK1A1 33/4885IKZF2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.